HIV infection and lipids

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• HIV infection and antiretroviral therapy (ART) contribute to dyslipidemia and cardiovascular disease (CVD) risk.
• Older ART regimens were associated with higher lipid abnormalities, while newer therapies are more lipid-friendly.
• Increased life expectancy in HIV patients leads to a rise in non-HIV related complications like CVD.

Purpose of the Study:

• To review the role of dyslipidemia in CVD among HIV-infected patients.
• To discuss traditional CVD risk factors, HIV-specific risks, and ART-induced dyslipidemia.

Main Methods:

• Literature review and expert commentary on dyslipidemia in HIV.
• Analysis of risk factors contributing to CVD in the HIV population.
• Discussion of current and emerging ART strategies and their lipid impact.

Main Results:

• HIV patients face complex CVD risk due to infection and ART.
• Advancements in ART have improved life expectancy but shifted mortality towards non-HIV complications like CVD.
• Ongoing studies are investigating interventions for dyslipidemia in HIV.

Conclusions:

• All HIV patients require CVD risk assessment before initiating ART.
• Selection of lipid-friendly ART regimens is recommended.
• Intervention for associated CVD risk factors, including lipids, hypertension, and smoking, is essential.